Oxytetracycline
Oxy-kesso-tetra, Terra-cortril, Terramycin (oxytetracycline) is a small molecule pharmaceutical. Oxytetracycline was first approved as Terra-cortril on 1982-01-01. It is used to treat acne vulgaris, bacterial infections, borrelia infections, chlamydia infections, and gonorrhea amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxytetracycline hydrochloride
Oxytetracycline
Oxytetracycline hydrochloride
+
Polymyxin b sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TERRAMYCIN W/ POLYMYXIN B SULFATE | Casper Pharma | N-061015 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Show 38 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB25: Oxytetracycline
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AA: Tetracycline and derivatives, topical antibiotics
— D06AA03: Oxytetracycline
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AA: Antibiotics, gynecological
— G01AA07: Oxytetracycline
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA06: Oxytetracycline
— J01AA56: Oxytetracycline, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA04: Oxytetracycline
HCPCS
Code | Description |
|---|---|
| J2460 | Injection, oxytetracycline hcl, up to 50 mg |
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | — | — | 1 | — | 1 |
| Wilms tumor | D009396 | EFO_0000212 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | 1 | 2 | 1 | — | — | 2 |
| Burns | D002056 | — | T30.0 | — | 1 | 1 | — | — | 1 |
| Eye burns | D005126 | EFO_1001788 | — | — | 1 | 1 | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | — | — | 1 |
| Furunculosis | D005667 | — | L02.92 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immune system diseases | D007154 | — | D89.9 | 1 | 1 | — | — | — | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | 1 | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | 1 | — | — | — | 1 |
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | 1 | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | 1 | — | — | — | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | 1 | — | — | — | 1 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | 1 | 1 | — | — | — | 1 |
| Hereditary eye diseases | D015785 | — | — | 1 | 1 | — | — | — | 1 |
| Hyperthyroidism | D006980 | — | E05.9 | 1 | 1 | — | — | — | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Basal cell carcinoma | D002280 | — | — | — | — | — | — | 1 | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | — | 1 | 1 |
| Basal cell neoplasms | D018295 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxytetracycline |
| INN | oxytetracycline |
| Description | Oxytetracycline is a tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae. It has a role as an antibacterial drug, a protein synthesis inhibitor, an antimicrobial agent, an anti-inflammatory drug and a bacterial metabolite. It is a tautomer of an oxytetracycline zwitterion. |
| Classification | Small molecule |
| Drug class | antibiotics (tetracycline derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 79-57-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1517 |
| ChEBI ID | 27701 |
| PubChem CID | 54675779 |
| DrugBank | DB00595 |
| UNII ID | SLF0D9077S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Oxytetracycline
+
Hydrocortisone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Oxytetracycline
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,551 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
353 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use